In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enject's GlucaPen: Mightier than the Hypo-kit?

Executive Summary

Decades after recombinant insulin first hit the market insulin is still big business. But in the race to lock up that market, the big players haven't done much to address a key problem with treating high blood sugar with insulin--a better way to inject the hormone glucagon when blood sugar levels drop way too low, or hypoglycemia. Enter Enject. The start-up has amassed exclusive worldwide commercial licenses to several pieces of technology that have enabled it to develop an auto-injector pen similar to the EpiPen, which is used to administer epinephrine in the event of severe allergic reactions. Enject hopes it can parlay its nifty device into a lucrative business development deal with one of the big insulin drug or device players.

You may also be interested in...



Don’t Forget Injectable Insulin, Novo Nordisk Says

In the rush to develop new diabetes drugs, big pharma's focus has been mainly on anti-diabetic agents that prolong a patient's transition to insulin or on developing easier routes of administration for insulin that do away with the need for pesky needles

Can Oral GLP-1 Be More than Just Convenient?

Given the collapse of all the inhaled insulin collaborations, many observers are skeptical that the Novo/Emisphere collaboration to create an oral version of Novo's liraglutide GLP-1 -- the drug-delivery company's biggest deal ever -- will work out any better. GLP-1, however, doesn't have all the baggage of insulin therapy, so there is in fact better logic for an oral pill's success. Still, if the program creates merely an oral version of once-a-day liraglutide, with no clinical advantages over its GLP-1 competitors, it will die just as certainly as did inhaled insulin.

Death to the Primary Care Blockbuster? What 2007 Says About the Future of the Drug Industry

The pharmaceutical industry just had its worst year of growth since 1961, and it doesn't look like there are enough primary care blockbuster launches in 2008 to turn those numbers around. The big lesson from 2007: specialty care is increasingly where pharma needs to be.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV003271

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel